Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT04572815 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT04572815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 14, 2021
Completion date
June 30, 2027
Enrollment
116 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic and lymphocytic disorder, hematopoietic and lymphoid system neoplasm